Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENXFree Report) in a report issued on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Price Performance

NASDAQ:TENX opened at $3.02 on Friday. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $61.20. The company’s 50 day moving average is $3.50 and its 200-day moving average is $7.72.

Tenax Therapeutics (NASDAQ:TENXGet Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.72). Sell-side analysts forecast that Tenax Therapeutics will post -7.96 EPS for the current year.

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Featured Stories

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.